Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Receptos Inc.

Division of Celgene Corp.
receptos.com

Latest From Receptos Inc.

Finance Watch: Gossamer, Alector And Harpoon Launch First Biopharma IPOs Of 2019

Public Company Edition: Grossing $276m, Gossamer would have been the third-largest biopharma IPO in the US if it had launched last year. Also, recent public company financings include debt and follow-on offerings; and two more firms cut jobs – Capricor and Seres.

Financing Business Strategies

Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO

Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.

Financing Business Strategies

IPO Update: Returns Run Red For Most Biopharma Firms That Went Public In The US Last Year

Nearly two-thirds of the 67 drug developers that launched an IPO in 2018 were trading below their offering price at the end of the year, bringing the average return to -7.5%. Even so, biopharma companies continue to line up for a US stock market debut.

Financing Business Strategies

Bristol Values Celgene's Hematology, Immunology Portfolio At $74bn, But Does It Price In Risk?

Bristol's surprising purchase diversifies its portfolio beyond Opdivo, while stopping Celgene's ongoing stock price declines after several setbacks. While Bristol execs downplayed the mid-term risk of generics for Celgene's blockbuster Revlimid, they highlighted near- and long-term growth drivers.

M & A Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
  • Therapeutic Areas
  • Gastrointestinal
  • Immune Disorders
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Receptor Pharmaceuticals Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Celgene Corp.
  • Senior Management
  • Faheem Hasnain, Pres. & CEO
    Graham Cooper, CFO
    Chrysa Mineo, SVP, Corp. Dev.
    Shelia Gujrathi, MD, CMO
    Robert J Peach, PhD, CSO
    Marcus T Boehm, PhD, CTO
  • Contact Info
  • Receptos Inc.
    Phone: (858) 652-5700
    3033 Science Park Rd.
    Ste. 300
    San Diego, CA 92121
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register